Sanofi-owned Aventis Pharma has received approval for its type 1 diabetes (T1D) drug, Tzield (teplizumab), from the UK Medicines and Healthcare products Regulatory Agency (MHRA). This authorisation ...

PARIS - The U.S. Food and Drug Administration has accepted Sanofi’s supplemental biologics license application for Tzield for expedited review under the Commissioner’s National Priority Voucher pilot ...

The application seeks approval for Tzield (teplizumab-mzwv) to delay the progression of stage 3 type 1 diabetes in adults and pediatric patients eight years and older who have been recently diagnosed ...

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the ...

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the ...

The U.S. Food and Drug Administration has approved a supplemental biologics license application for Sanofi’s (SNY) Tzield (teplizumab-mzwv), expanding its use to patients as young as one year old to ...

What Is Tzield, and Why Does It Matter? Tzield (teplizumab-mzwv) is an immune therapy that can help delay the progression of type 1 diabetes (T1D) in people who are at high risk. The FDA has now ...